Author

D. P. Porter

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:drug response / drug discovery· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 2 Organism:virus· 2 Assay:bulk RNA-seq· 1 Organism:mouse· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

J. K. Perry· 3 shared J. Li· 3 shared J. P. Bilello· 3 shared T. Cihlar· 3 shared V. Du Pont· 3 shared X. Lu· 3 shared A. J. Pruijssers· 2 shared A. S. George· 2 shared

Activity by Year

2020-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

J. K. Perry

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variants

J. Pitts, J. Li, J. Perry, V. Du Pont, N. Riola, L. Rodriguez, X. Lu, C. Kurhade, X. Xie, G. Camus, S. Manhas, R. Martin, P.-Y. Shi, T. Cihlar, D. P. Porter, , J. P. Bilello

This study assesses the antiviral activity of remdesivir and GS-441524 against multiple SARS-CoV-2 variants, finding they remain effective against Delta, Omicron, and other variants.

bioRxiv · Feb 9, 2022Microbiology

In Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance.

L. Checkmahomed, V. Du Pont, N. C. Riola, J. Perry, J. Li, D. P. Porter, G. Boivin

This study shows that remdesivir resistance in SARS-CoV-2 develops slowly, with a single mutation conferring limited resistance.

bioRxiv · Feb 7, 2022Microbiology

Distinct genetic determinants and mechanisms of SARS-CoV-2 resistance to remdesivir

L. J. Stevens, A. J. Pruijssers, H. W. Lee, C. J. Gordon, E. P. Tchesnokov, J. Gribble, A. S. George, T. M. Hughes, X. Lu, J. Li, J. K. Perry, D. P. Porter, T. Cihlar, T. P. Sheahan, R. S. Baric, , M. R. Denison

This study identifies distinct mutations in SARS-CoV-2's RdRp that confer remdesivir resistance, showing their biochemical mechanisms and transferability to other coronaviruses.

bioRxiv · Jan 25, 2022 · PreprintMicrobiology

Efficient incorporation and template-dependent polymerase inhibition are major determinants for the broad-spectrum antiviral activity of remdesivir

M. Götte, C. J. Gordon, H. W. Lee, E. P. Tchesnokov, J. K. Perry, J. Y. Feng, J. P. Bilello, D. P. Porter

This study investigates how remdesivir's antiviral activity varies across RNA viruses by analyzing its incorporation and inhibition mechanisms in different polymerases.

bioRxiv · Oct 14, 2021Biochemistry

Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice.

A. J. Pruijssers, A. S. George, A. Schäfer, S. R. Leist, L. E. Gralinski, K. H. Dinnon, B. L. Yount, M. L. Agostini, L. J. Stevens, J. D. Chappell, X. Lu, T. M. Hughes, K. L. Gully, D. R. Martinez, A. J. Brown, , T. P. Sheahan

This study shows remdesivir effectively inhibits SARS-CoV-2 in human cells and mice, reducing viral load and improving lung function.

bioRxiv · Apr 27, 2020Microbiology